SCHEMBL737880

SCHEMBL737880

C=C(C)n1c(=O)[nH]c2cnccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 3/20 0.47
FEN1 P39748 1/20 0.42
TNKS O95271 7/20 0.39
TNKS2 Q9H2K2 1/20 0.38
PARP1 P09874 1/20 0.37
KDM5A P29375 2/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
CHUK O15111 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
IKBKB O14920 1/20 0.34
AURKA O14965 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PIM1 P11309 1/20 0.34
TOP1 P11387 1/20 0.34
GABRA1 P14867 1/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11688619 0.79 DAO (0.49) DAOFEN1TNKSTNKS2PARP1
SCHEMBL29356336 0.77 DAO (0.55) DAO
SCHEMBL507863 0.77 DAO (0.55) DAO
SCHEMBL6215203 0.76 DAO (0.42) DAOFEN1TNKSTNKS2GABRG2
SCHEMBL11231429 0.76 DAO (0.53) DAO
SCHEMBL4312246 0.75 DAO (0.50) DAOFEN1TNKSTNKS2ADORA3
SCHEMBL9979916 0.73 DAO (0.45) DAOFEN1TNKSTNKS2PARP1
SCHEMBL11197239 0.73 DAO (0.61) DAOAURKA
SCHEMBL16657358 0.72 DAO (0.47) DAOFEN1TNKSTNKS2PARP1
SCHEMBL7230997 0.72 DAO (0.59) DAOFEN1KDM4EGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310573-A1 Stabilized Vaccine Compositions JANSSEN VACCINES AND PREVENTION B.V. (NL) 2023-10-05 US disclosed
US-8138177-B2 Benzimidazolone derivatives as CB2 receptor ligands PFIZER INC. (US) 2012-03-20 US disclosed
EP-1861377-B1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER (US) 2010-12-29 EP disclosed
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES PFIZER INC 2009-12-03 US disclosed
EP-2114897-A2 BENZIMIDAZOLONE DERIVATIVES Pfizer Products Inc. (US) 2009-11-11 EP disclosed
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS ANDO KAZUO 2009-07-16 US disclosed
WO-2008032164-A2 BENZIMIDAZOLONE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES TRPV1, CNR1, CNR2 DAO 4401/4885FEN1 4836/4885TNKS 1422/4885
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS TRPV1, CNR1, CNR2 DAO 4549/4885FEN1 4878/4885TNKS 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.